What is QuantHealth?
QuantHealth operates at the intersection of artificial intelligence and life sciences, providing a sophisticated platform that simulates clinical scenarios to optimize pharmaceutical research. By synthesizing biomedical, clinical, and epidemiological data, the company enables stakeholders to forecast enrollment, refine trial protocols, and assess drug assets with unprecedented precision. This technology addresses critical inefficiencies in the drug development lifecycle, positioning QuantHealth as a vital partner for biotechnology and pharmaceutical enterprises seeking to enhance decision-making and reduce time-to-market for life-saving therapies.
How much funding has QuantHealth raised?
QuantHealth has raised a total of $64.6M across 3 funding rounds:
Angel/Seed
$2.6M
Series A
$17M
Series B
$45M
Angel/Seed (2022): $2.6M with participation from Pitango Venture Capital, Atooro Fund, Nina Capital, and Bessemer Venture Partners
Series A (2024): $17M led by Boston Millennia Partners, Pitango Venture Capital, Nina Capital, Accenture Technology Ecosystem & Ventures, and Bertelsmann Digital Media Investments
Series B (2026): $45M supported by Bertelsmann SE, Shoni Health Ventures, Artofin Venture Capital Fund, Sanofi Ventures, Pitango Venture Capital, Esplanade Ventures, and Qumra Capital
Key Investors in QuantHealth
Pitango Venture Capital
A prominent venture capital firm that partners with visionary entrepreneurs, supporting companies from stealth mode through to maturity with a dedicated focus on the healthtech sector.
Sanofi Ventures
The corporate venture capital arm of Sanofi, specializing in early-stage biotech and digital health investments that align with transformative medical technologies.
Nina Capital
A specialized venture capital firm focused on health technology, providing strategic capital to founders aiming to revolutionize healthcare through information technology.
What's next for QuantHealth?
With the successful closure of its Series B round, QuantHealth is poised to scale its operations and expand its global footprint. The company intends to leverage this capital to enhance its proprietary AI models and deepen its integration within the pharmaceutical R&D ecosystem. By focusing on high-impact clinical trial simulations, QuantHealth is well-positioned to lead the digital transformation of drug development, moving toward a future where virtual patient populations become the standard for evaluating treatment efficacy and safety.
See full QuantHealth company page
